Molecular Basis of Differences Among Statins and a Comparison with Antioxidant Vitamins

American Journal of Cardiology

Volumn 98, Issue 11 SUPPL., 2006, Pages

  Mason, R Preston ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; ATORVASTATIN; BETA CAROTENE; CERIVASTATIN; FLUINDOSTATIN; GLIBENCLAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN; RETINOL; ROSUVASTATIN; SIMVASTATIN; TETRYLAMMONIUM; TROLOX C; VITAMIN;

APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE EXACERBATION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG SOLUBILITY; DRUG STRUCTURE; ENDOTHELIUM; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPHILICITY; NONHUMAN; OUTCOME ASSESSMENT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; STROKE; TREATMENT OUTCOME;

ANTIOXIDANTS; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRAVASTATIN; PYRIDINES; PYRROLES; VITAMINS;

EID: 33751183978     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.09.018     Document Type: Article

References (83)

1. Fonarow G.C., and Watson K.E. Effective strategies for long-term statin use. Am J Cardiol 92 suppl (2003) 27i-34i
2. Kinlay S., and Egido J. Inflammatory biomarkers in stable atherosclerosis. Am J Cardiol 98 suppl (2006) 2P-8P
3. Tsimikas S. Oxidative biomarkers in diagnosis and prognosis of cardiovascular disease. Am J Cardiol 98 suppl (2006) 9P-17P
4. Ray K.K., Cannon C.P., and Ganz P. Beyond lipid lowering: what have we learned about the benefits of statins from the acute coronary syndromes trials?. Am J Cardiol 98 suppl (2006) 18P-25P
5. Libby P., and Sasiela W. Plaque stabilization: can we turn theory into evidence?. Am J Cardiol 98 suppl (2006) 26P-33P
6. Mason R.P., Walter M.F., Day C.A., and Jacob R.F. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol 96 (2005) 11-23
7. Goldstein J.L., and Brown M.S. Progress in understanding the LDL receptor and HMG-CoA reductase, two membrane proteins that regulate the plasma cholesterol. J Lipid Res 25 (1984) 1450-1461
8. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19 (2005) 117-125
9. Bellosta S., Paoletti R., and Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109 (2004) III50-III57
10. Prueksaritanont T., Zhao J.J., Ma B., Roadcap B.A., Tang C., Qiu Y., Liu L., Lin J.H., Pearson P.G., and Baillie T.A. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 301 (2002) 1042-1051
11. Davignon J., and Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 109 (2004) III27-III32
12. Laufs U., Fata V.L., and Liao J.K. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 272 (1997) 31725-31729
13. Laufs U., and Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273 (1998) 24266-24271
14. Ohara Y., Peterson T.E., and Harrison D.G. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 91 (1993) 2546-2551
15. Laufs U., Wassmann S., Hilgers S., Ribaudo N., Bohm M., and Nickenig G. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 88 (2001) 1306-1307
16. Wassmann S., Faul A., Hennen B., Scheller B., Bohm M., and Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res 93 (2003) e98-e103
17. Laufs U., La Fata V., Plutzky J., and Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
18. Feron O., Dessy C., Desager J.P., and Balligand J.L. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 103 (2001) 113-118
19. Gargalovic P., and Dory L. Cellular apoptosis is associated with increased caveolin-1 expression in macrophages. J Lipid Res 44 (2003) 1622-1632
20. Uydeş-Doǧan B.S., Topal G., Takir S., Alp F.I., Kaleli D., and Ozdemir O. Relaxant effects of pravastatin, atorvastatin and cerivastatin on isolated rat aortic rings. Life Sci 76 (2005) 1771-1786
21. John S., Schneider M.P., Delles C., Jacobi J., and Schmieder R.E. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. [clinical investigation]. Am Heart J 149 (2005) 473
22. Braun-Dullaeus R.C., Mann M.J., and Dzau V.J. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation 98 (1998) 82-89
23. Corsini A., Arnaboldi L., Raiteri M., Quarato P., Faggiotto A., Paoletti R., and Fumagalli R. Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes. Pharmacol Res 33 (1996) 55-61
24. Negre-Aminou P., van Vliet A.K., van Erck M., van Thiel G.C., van Leeuwen R.E., and Cohen L.H. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta 1345 (1997) 259-268
25. Axel D.I., Riessen R., Runge H., Viebahn R., and Karsch K.R. Effects of cerivastatin on human arterial smooth muscle cell proliferation and migration in transfilter cocultures. J Cardiovasc Pharmacol 35 (2000) 619-629
26. Stark Jr. W.W., Blaskovich M.A., Johnson B.A., Qian Y., Vasudevan A., Pitt B., Hamilton A.D., Sebti S.M., and Davies P. Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells. Am J Physiol 275 (1998) L55-L63
27. Takemoto M., and Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21 (2001) 1712-1719
28. Yang Z., Kozai T., van der Loo B., Viswambharan H., Lachat M., Turina M.I., Malinski T., and Luscher T.F. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J Am Coll Cardiol 36 (2000) 1691-1697
29. Fukumoto Y., Libby P., Rabkin E., Hill C.C., Enomoto M., Hirouchi Y., Shiomi M., and Aikawa M. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation 103 (2001) 993-999
30. Soma M.R., Donetti E., Parolini C., Mazzini G., Ferrari C., Fumagalli R., and Paoletti R. HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thromb 13 (1993) 571-578
31. Rossi M.L., Marziliano N., Merlini P.A., Bramucci E., Canosi U., Belli G., Parenti D.Z., Mannucci P.M., and Ardissino D. Different quantitative apoptotic traits in coronary atherosclerotic plaques from patients with stable angina pectoris and acute coronary syndromes. Circulation 110 (2004) 1767-1773
32. Shiomi M., Ito T., Hirouchi Y., and Enomoto M. Fibromuscular cap composition is important for the stability of established atherosclerotic plaques in mature WHHL rabbits treated with statins. Atherosclerosis 157 (2001) 75-84
33. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., and Skene A.M. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
34. Nicholls S.J., Cutri B., Worthley S.G., Kee P., Rye K.A., Bao S., and Barter P.J. Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 25 (2005) 2416-2421
35. Vincent L., Chen W., Hong L., Mirshahi F., Mishal Z., Mirshahi-Khorassani T., Vannier J.P., Soria J., and Soria C. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett 495 (2001) 159-166
36. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D.J., Sessa W.C., and Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6 (2000) 1004-1010
37. Weis M., Heeschen C., Glassford A.J., and Cooke J.P. Statins have biphasic effects on angiogenesis. Circulation 105 (2002) 739-745
38. Goligorsky M.S., Budzikowski A.S., Tsukahara H., and Noiri E. Co-operation between endothelin and nitric oxide in promoting endothelial cell migration and angiogenesis. Clin Exp Pharmacol Physiol 26 (1999) 269-271
39. Kaneta S., Satoh K., Kano S., Kanda M., and Ichihara K. All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells. Atherosclerosis 170 (2003) 237-243
40. Edinger A.L., and Thompson C.B. Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol 16 (2004) 663-669
41. von Tresckow B., Kallen K.J., von Strandmann E.P., Borchmann P., Lange H., Engert A., and Hansen H.P. Depletion of cellular cholesterol and lipid rafts increases shedding of CD30. J Immunol 172 (2004) 4324-4331
42. Ghittoni R., Patrussi L., Pirozzi K., Pellegrini M., Lazzerini P.E., Capecchi P.L., Pasini F.L., and Baldari C.T. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. FASEB J 19 (2005) 605-607
43. Vasa M., Fichtlscherer S., Adler K., Aicher A., Martin H., Zeiher A.M., and Dimmeler S. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103 (2001) 2885-2890
44. Llevadot J., Murasawa S., Kureishi Y., Uchida S., Masuda H., Kawamoto A., Walsh K., Isner J.M., and Asahara T. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 108 (2001) 399-405
45. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 346 (1995) 1647-1653
46. Iso H., Jacobs Jr. D.R., Wentworth D., Neaton J.D., and Cohen J.D. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med 320 (1989) 904-910
47. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet 352 (1998) 1801-1807
48. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J., and for the West of Scotland Coronary Prevention Study [WOSCOPS] Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
49. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., and Gotto Jr. A.M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS [Air Force/Texas Coronary Atherosclerosis Prevention Study]. JAMA 279 (1998) 1615-1622
50. Law M.R., Wald N.J., and Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. [paper]. BMJ 326 (2003) 1423-1427
51. Bucher H.C., Griffith L.E., and Guyatt G.H. Effect of HMGcoA reductase inhibitors on stroke: a meta-analysis of randomized, controlled trials. Ann Intern Med 128 (1998) 89-95
52. Blauw G.J., Lagaay A.M., Smelt A.H., and Westendorp R.G. Stroke, statins, and cholesterol: a meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 28 (1997) 946-950
53. Amarenco P., Labreuche J., Lavallee P., and Touboul P.J. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35 (2004) 2902-2909
54. Espeland M.A., O'Leary D.H., Terry J.G., Morgan T., Evans G., and Mudra H. Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. [review]. Curr Control Trials Cardiovasc Med 6 (2005) 3
55. Atkins D., Psaty B.M., Koepsell T.D., Longstreth Jr. W.T., and Larson E.B. Cholesterol reduction and the risk for stroke in men: a meta-analysis of randomized, controlled trials. Ann Intern Med 119 (1993) 136-145
56. Endres M., Laufs U., Huang Z., Nakamura T., Huang P., Moskowitz M.A., and Liao J.K. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 95 (1998) 8880-8885
57. Laufs U., Gertz K., Huang P., Nickenig G., Bohm M., Dirnagl U., and Endres M. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 31 (2000) 2442-2449
58. Amin-Hanjani S., Stagliano N.E., Yamada M., Huang P.L., Liao J.K., and Moskowitz M.A. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 32 (2001) 980-986
59. Laufs U., Gertz K., Dirnagl U., Bohm M., Nickenig G., and Endres M. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 942 (2002) 23-30
60. Carr A.C., McCall M.R., and Frei B. Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol 20 (2000) 1716-1723
61. Wagner A.H., Kohler T., Ruckschloss U., Just I., and Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 20 (2000) 61-69
62. Wassmann S., Laufs U., Muller K., Konkol C., Ahlbory K., Baumer A.T., Linz W., Bohm M., and Nickenig G. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 22 (2002) 300-305
63. Yamamoto A., Hoshi K., and Ichihara K. Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes. Eur J Pharmacol 361 (1998) 143-149
64. Girona J., La Ville A.E., Sola R., Plana N., and Masana L. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol 83 (1999) 846-851
65. Aviram M., Rosenblat M., Bisgaier C.L., and Newton R.S. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 138 (1998) 271-280
66. Mason R.P., Walter M.F., and Jacob R.F. Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation 109 (2004) II34-II41
67. Mason R.P., Walter M.F., Day C.A., and Jacob R.F. Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism. J Biol Chem 281 (2006) 9337-9345
68. Krinsky N.I., Cronwell D.G., and Oncley J.L. The transport of vitamin A and carotenoids in human plasma. Arch Biochem Biophys 73 (1958) 233-246
69. Bjornson L.K., Kayden H.J., Miller E., and Moshell A.N. The transport of α-tocopherol and β-carotene in human blood. J Lipid Res 17 (1976) 343-352
70. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330 (1994) 1029-1035
71. Omenn G.S., Goodman G.E., Thornquist M.D., Balmes J., Cullen M.R., Glass A., Keogh J.P., Meyskens F.L., Valanis B., Williams J.H., Barnhart S., and Hammar S. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334 (1996) 1150-1155
72. Stephens N.G., Parsons A., Schofield P.M., Kelly F., Cheeseman K., and Mitchinson M.J. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347 (1996) 781-786
73. Yusuf S., Dagenais G., Pogue J., Bosch J., Sleight P., and Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 154-160
74. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 23-33
75. Brown B.G., Zhao X.Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., Dowdy A.A., Marino E.K., Bolson E.L., Alaupovic P., Frohlich J., and Albers J.J. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
76. Waters D.D., Alderman E.L., Hsia J., Howard B.V., Cobb F.R., Rogers W.J., Ouyang P., Thompson P., Tardif J.C., Higginson L., et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 288 (2002) 2432-2440
77. Micheletta F., Natoli S., Misuraca M., Sbarigia E., Diczfalusy U., and Iuliano L. Vitamin E supplementation in patients with carotid atherosclerosis: reversal of altered oxidative stress status in plasma but not in plaque. Arterioscler Thromb Vasc Biol 24 (2004) 136-140
78. Upston J.M., Terentis A.C., and Stocker R. Tocopherol-mediated peroxidation of lipoproteins: implications for vitamin E as a potential antiatherogenic supplement. FASEB J 13 (1999) 977-994
79. Podmore I.D., Griffiths H.R., Herbert K.E., Mistry N., Mistry P., and Lunec J. Vitamin C exhibits pro-oxidant properties. [scientific correspondence]. Nature 392 (1998) 559
80. Steinberg D. Clinical trials of antioxidants in atherosclerosis: are we doing the right thing?. Lancet 346 (1995) 36-38
81. Matthan N.R., Giovanni A., Schaefer E.J., Brown B.G., and Lichtenstein A.H. Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL. J Lipid Res 44 (2003) 800-806
82. Cheung M.C., Zhao X.Q., Chait A., Albers J.J., and Brown B.G. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol 21 (2001) 1320-1326
83. 1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 23 (2003) 847-852